Global /United States /Healthcare /Biotechnology /XBIT

XBiotech Inc.

XBIT

• NASDAQ: XBIT • Delayed

2.56USD 0.8%

As of 13 June 2026, XBiotech Inc. has a market cap of $78.05M USD, ranking #27320 globally and #4149 in the United States. It ranks #2454 in the Healthcare sector, and #473 in the Biotechnology industry.

Global Rank

27320

Country Rank

4149

Sector Rank

2454

Industry Rank

473

Key Stats

Market Cap

$78.05MUSD

Enterprise Value

-$48.11MUSD

EBITDA (TTM)

-$54.0MUSD

Net Income (TTM)

-$45.54MUSD

PB Ratio

0.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Sushma Shivaswamy open_in_new

Employees

Founded

2005

IPO

15 Apr 2015

Website

xbiotech.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.8%	1.2%	13%	-3%	7.1%	7.1%	-11%	-26%	-86%

News

XBIT Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	XBIT XBiotech Inc ISIN: CA98400H1029 Shares Out.: Shares Outstanding: 30.488M¹ Shares Float: 23.071M² TV: TradingView: NASDAQ: XBIT SA: Stock Analysis: NASDAQ: XBIT YF: Yahoo Finance: XBIT GF: Google Finance: NASDAQ: XBIT NQ: NASDAQ: XBIT BA: Barron's: XBIT MS: Morningstar: XNAS: XBIT	2.56 USD	TV: TradingView: NASDAQ: XBIT SA: Stock Analysis: NASDAQ: XBIT YF: Yahoo Finance: XBIT GF: Google Finance: NASDAQ: XBIT NQ: NASDAQ: XBIT BA: Barron's: XBIT MS: Morningstar: XNAS: XBIT

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 234K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 205K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 35K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 34K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 32K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 23K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 61K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 57K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 54K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 54K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 36K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 33K%	-	Germany

chevron_leftBack